Tonix Pharmaceuticals, Inc.’s (NASDAQ: TNXP) ($TNXP) interview with Dr. Seth Lederman, MD, and CEO


Dr. Seth Lederman, MD, CEO of Tonix Pharmaceuticals, Inc. (NASDAQ: TNXP) ($TNXP), is at the Nasdaq Marketplace studio, talking with New to The Street’s TV Host Jane King. As a clinical-stage biopharmaceutical Company, Seth informs viewers that the FDA approved an IND clearance for TNX-601 for human depression. The Company is developing a time-released pill, a once-a-day dose, as a new first-line potential treatment for those inflicted with depression. The pill’s formulation uses the compound tianeptine. Europe, Latin America, and Asia countries for about 30-years used this compound to treat those depressed. Johnson & Johnson, about 15 years ago, acquired a company to move forward with necessary U.S. FDA studies and clinical approvals to use tianeptine, but their efforts stopped. TNXP anticipates moving TNX-601’s IND stage forward to a Phase 2 trial sometime beginning of next year, 2023. Tonix has many pipeline drugs in development. Its lead product TNX-102 SL completed its first part of its Fibromyalgia FDA Phase 3 clinical trial and is moving forward with all the necessary FDA rules with the expectation to achieve a new drug approval status. Two-thirds of Long-Covid patients have multi-site pain, similar to those who have Fibromyalgia. Tonix is moving forward with an FDA Phase 2 Long-Covid prevail study for its TNX-102 SL. Also, those with Chronic Fatigue Syndrome (CFS) could use TNX-102SL if approved to treat accordingly. Tonix Pharmaceuticals is developing many drugs to treat central nervous system disorders and diseases. The on-screen QR code is available during the show; download or visit Tonix Pharmaceuticals, Inc. –

To make sure you never miss a video from New to the Street, click here to subscribe:

Follow New to the Street on Twitter:

Follow New to the Street on Facebook:

Follow New to the Street on Instagram:

Follow New to the Street on Rumble:

About New to the Street:

Subscribe to our Mailing List: